Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors

J. A. McCubrey, M. Milella, A. Tafuri, A. M. Martelli, P. Lunghi, A. Bonati, M. Cervello, J. T. Lee, L. S. Steelman

Research output: Contribution to journalArticle

Abstract

Mutations occur in some cancer cells and result in elevated expression or constitutive activation of various growth factor receptors. The Raf/MEK/ERK pathway is often activated by mutations in these growth factor receptors. This pathway is regulated by upstream Ras, which is mutated in 20 to 30% of human cancers. B-Raf is also activated by mutation, especially in melanoma and thyroid cancers. Many of the events elicited by the Raf/MEK/ERK pathway have direct effects on survival and proliferative pathways. Aberrant regulation of the Raf/MEK/ERK pathway can contribute to uncontrolled cell growth and lead to malignant transformation. The effective targeting of this pathway may result in the suppression of cell growth, and death of malignant cells. This review focuses on targeting the Raf/MEK/ERK pathway with small-molecule inhibitors for the treatment of cancer.

Original languageEnglish
Pages (from-to)614-630
Number of pages17
JournalCurrent Opinion in Investigational Drugs
Volume9
Issue number6
Publication statusPublished - Jun 2008

Fingerprint

MAP Kinase Signaling System
Growth Factor Receptors
Mutation
Neoplasms
Growth
Thyroid Neoplasms
Melanoma
Cell Death
Survival

Keywords

  • Apoptosis
  • Cancer
  • ERK
  • Inhibitor
  • MEK
  • Raf
  • Signal transduction

ASJC Scopus subject areas

  • Pharmacology

Cite this

McCubrey, J. A., Milella, M., Tafuri, A., Martelli, A. M., Lunghi, P., Bonati, A., ... Steelman, L. S. (2008). Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. Current Opinion in Investigational Drugs, 9(6), 614-630.

Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. / McCubrey, J. A.; Milella, M.; Tafuri, A.; Martelli, A. M.; Lunghi, P.; Bonati, A.; Cervello, M.; Lee, J. T.; Steelman, L. S.

In: Current Opinion in Investigational Drugs, Vol. 9, No. 6, 06.2008, p. 614-630.

Research output: Contribution to journalArticle

McCubrey, JA, Milella, M, Tafuri, A, Martelli, AM, Lunghi, P, Bonati, A, Cervello, M, Lee, JT & Steelman, LS 2008, 'Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors', Current Opinion in Investigational Drugs, vol. 9, no. 6, pp. 614-630.
McCubrey JA, Milella M, Tafuri A, Martelli AM, Lunghi P, Bonati A et al. Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. Current Opinion in Investigational Drugs. 2008 Jun;9(6):614-630.
McCubrey, J. A. ; Milella, M. ; Tafuri, A. ; Martelli, A. M. ; Lunghi, P. ; Bonati, A. ; Cervello, M. ; Lee, J. T. ; Steelman, L. S. / Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. In: Current Opinion in Investigational Drugs. 2008 ; Vol. 9, No. 6. pp. 614-630.
@article{bebe5fb3f7d64075ae120a09576afc13,
title = "Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors",
abstract = "Mutations occur in some cancer cells and result in elevated expression or constitutive activation of various growth factor receptors. The Raf/MEK/ERK pathway is often activated by mutations in these growth factor receptors. This pathway is regulated by upstream Ras, which is mutated in 20 to 30{\%} of human cancers. B-Raf is also activated by mutation, especially in melanoma and thyroid cancers. Many of the events elicited by the Raf/MEK/ERK pathway have direct effects on survival and proliferative pathways. Aberrant regulation of the Raf/MEK/ERK pathway can contribute to uncontrolled cell growth and lead to malignant transformation. The effective targeting of this pathway may result in the suppression of cell growth, and death of malignant cells. This review focuses on targeting the Raf/MEK/ERK pathway with small-molecule inhibitors for the treatment of cancer.",
keywords = "Apoptosis, Cancer, ERK, Inhibitor, MEK, Raf, Signal transduction",
author = "McCubrey, {J. A.} and M. Milella and A. Tafuri and Martelli, {A. M.} and P. Lunghi and A. Bonati and M. Cervello and Lee, {J. T.} and Steelman, {L. S.}",
year = "2008",
month = "6",
language = "English",
volume = "9",
pages = "614--630",
journal = "Current Opinion in Investigational Drugs",
issn = "1472-4472",
publisher = "Current Drugs Ltd.",
number = "6",

}

TY - JOUR

T1 - Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors

AU - McCubrey, J. A.

AU - Milella, M.

AU - Tafuri, A.

AU - Martelli, A. M.

AU - Lunghi, P.

AU - Bonati, A.

AU - Cervello, M.

AU - Lee, J. T.

AU - Steelman, L. S.

PY - 2008/6

Y1 - 2008/6

N2 - Mutations occur in some cancer cells and result in elevated expression or constitutive activation of various growth factor receptors. The Raf/MEK/ERK pathway is often activated by mutations in these growth factor receptors. This pathway is regulated by upstream Ras, which is mutated in 20 to 30% of human cancers. B-Raf is also activated by mutation, especially in melanoma and thyroid cancers. Many of the events elicited by the Raf/MEK/ERK pathway have direct effects on survival and proliferative pathways. Aberrant regulation of the Raf/MEK/ERK pathway can contribute to uncontrolled cell growth and lead to malignant transformation. The effective targeting of this pathway may result in the suppression of cell growth, and death of malignant cells. This review focuses on targeting the Raf/MEK/ERK pathway with small-molecule inhibitors for the treatment of cancer.

AB - Mutations occur in some cancer cells and result in elevated expression or constitutive activation of various growth factor receptors. The Raf/MEK/ERK pathway is often activated by mutations in these growth factor receptors. This pathway is regulated by upstream Ras, which is mutated in 20 to 30% of human cancers. B-Raf is also activated by mutation, especially in melanoma and thyroid cancers. Many of the events elicited by the Raf/MEK/ERK pathway have direct effects on survival and proliferative pathways. Aberrant regulation of the Raf/MEK/ERK pathway can contribute to uncontrolled cell growth and lead to malignant transformation. The effective targeting of this pathway may result in the suppression of cell growth, and death of malignant cells. This review focuses on targeting the Raf/MEK/ERK pathway with small-molecule inhibitors for the treatment of cancer.

KW - Apoptosis

KW - Cancer

KW - ERK

KW - Inhibitor

KW - MEK

KW - Raf

KW - Signal transduction

UR - http://www.scopus.com/inward/record.url?scp=44649089666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44649089666&partnerID=8YFLogxK

M3 - Article

C2 - 18516761

AN - SCOPUS:44649089666

VL - 9

SP - 614

EP - 630

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1472-4472

IS - 6

ER -